SCHEMBL583270

SCHEMBL583270

COC(=O)c1cc(Br)nc(Br)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.64
ALDH1A1 P00352 2/20 0.64
CA1 P00915 4/20 0.54
CA2 P00918 4/20 0.54
CA12 O43570 3/20 0.54
CA7 P43166 3/20 0.54
CA9 Q16790 3/20 0.54
CA14 Q9ULX7 3/20 0.54
XDH P47989 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
GAA P10253 1/20 0.52
NFKB1 P19838 1/20 0.52
GFER P55789 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
FUT7 Q11130 1/20 0.52
NOTUM Q6P988 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12837985 0.90 KDM4E (0.58) KDM4EALDH1A1CA1CA2CA12
SCHEMBL568182 0.88 KDM4E (0.56) KDM4EALDH1A1CA1CA2CA12
SCHEMBL30014968 0.88 KDM4E (0.56) KDM4EALDH1A1CA1CA2CA12
SCHEMBL583987 0.88 ALDH1A1 (0.79) KDM4EALDH1A1CA1CA2CA12
SCHEMBL20488853 0.87 KDM4E (0.55) KDM4EALDH1A1CA1CA2CA12
SCHEMBL20488880 0.87 KDM4E (0.55) KDM4EALDH1A1CA1CA2CA12
SCHEMBL12853064 0.85 KDM4E (0.53) KDM4EALDH1A1CA1CA2CA12
SCHEMBL31662445 0.85 KDM4E (0.49) KDM4EALDH1A1CA1CA2CA12
SCHEMBL17544754 0.84 KDM4E (0.51) KDM4EALDH1A1CA1CA2CA12
SCHEMBL31662342 0.82 KDM4E (0.50) KDM4EALDH1A1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731207-A2 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2026-04-29 EP disclosed
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 EP disclosed
EP-4596550-A1 COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-06 EP disclosed
WO-2025149545-A1 HETEROARYLPHENYL ETHER DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2025-07-17 WO disclosed
WO-2025006293-A2 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2025-01-02 WO disclosed
EP-4472739-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2024-12-11 EP disclosed
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2024-09-26 US disclosed
WO-2024191996-A1 BICYCLIC UREAS AS KINASE INHIBITORS INCYTE CORPORATION (US) 2024-09-19 WO disclosed
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2024-04-18 US disclosed
EP-4263520-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2023-10-25 EP disclosed
WO-2010115836-A1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 WO disclosed
WO-2010115836-A1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 WO disclosed
US-20100261687-A1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
US-20100261687-A1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
US-20100261687-A1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
EP-2234969-A2 CARBAZOLE-BASED HOLE TRANSPORT AND /OR ELECTRON BLOCKING MATERIALS AND /OR HOST POLYMER MATERIALS Georgia Tech Research Corporation (US) 2010-10-06 EP disclosed
WO-2009150230-A1 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER NOVARTIS AG (CH) 2009-12-17 WO disclosed
WO-2009150230-A1 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER NOVARTIS AG (CH) 2009-12-17 WO disclosed
WO-2009080799-A2 CARBAZOLE-BASED HOLE TRANSPORT AND /OR ELECTRON BLOCKING MATERIALS AND /OR HOST POLYMER MATERIALS GEORGIA TECH RESEARCH CORPORATION (US) 2009-07-02 WO disclosed
WO-2009080799-A2 CARBAZOLE-BASED HOLE TRANSPORT AND /OR ELECTRON BLOCKING MATERIALS AND /OR HOST POLYMER MATERIALS GEORGIA TECH RESEARCH CORPORATION (US) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 PCSK9, PCSK7, PCSK6 KDM4E 3354/4885ALDH1A1 3487/4885CA1 3736/4885
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 KDM4E 800/4885ALDH1A1 3820/4885CA1 4241/4885
US-20100261687-A1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS CCR3, CCR1, CCR4 KDM4E 3679/4885ALDH1A1 876/4885CA1 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.